Do You Need to Wean Off Mounjaro Before Stopping?

What clinical trials found when tirzepatide was stopped

The clearest evidence on discontinuation comes from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which followed thousands of adults over 72 weeks and documented an average weight reduction of around 20–21% at the 15 mg dose. Critically, extension data from the SURMOUNT programme showed that when participants stopped tirzepatide after the active phase, a meaningful portion of the weight loss reversed over the following months. This is consistent with what clinicians observe across GLP-1 and dual-agonist medicines generally: the biological effects that suppress appetite and slow gastric emptying are tied to the drug being present. Remove it, and those effects diminish.

That does not mean stopping is wrong or that treatment must be lifelong for everyone. What it does mean is that stopping is a clinical moment worth planning, not an administrative one. There is no step-down protocol built into the tirzepatide prescribing guidance, the medicine does not create physical dependence, and abrupt cessation carries no danger comparable to stopping, say, a corticosteroid or beta-blocker. The concern is about what comes next metabolically, not about a discontinuation syndrome.

The NHS page on tirzepatide supports this framing, noting that patients should follow their prescriber's advice on when and how to stop, rather than making that call unilaterally.

Why appetite and weight often change after you stop

A common misconception worth addressing plainly: some people assume that once weight has come off, the body will simply hold it at that new level regardless of whether treatment continues. The evidence does not support that. Obesity is recognised as a chronic condition with strong biological drivers, hormonal signals that push appetite up and metabolic rate down when energy stores fall. Tirzepatide works partly by countering those signals through its dual action on GIP and GLP-1 receptors. When the medicine is no longer present, those counterbalancing signals fade.

This does not mean everyone regains all the weight they lost, and it is not a reason to avoid stopping if stopping is the right clinical choice. Lifestyle habits established during treatment, regular physical activity and sustained dietary changes all influence what happens next. Some patients also notice changes in their cycle when stopping or starting treatment, and if that applies to you, our page on whether Mounjaro can bring on a period explains what the evidence currently suggests. But understanding that the biology shifts is useful, it removes the self-blame that can follow if weight does creep back, and it frames the conversation with your prescriber honestly. If you have questions about what stopping might mean for you specifically, our frequently asked questions cover some of the most common concerns.

Do you have to wean yourself off Mounjaro gradually?

In the strict pharmacological sense, no. Tirzepatide's half-life is approximately five days, so the medicine clears from the body gradually over several weeks after the last injection, regardless of whether the final doses are reduced. There is no clinical evidence that taking a lower dose for a few weeks before stopping produces a better outcome than stopping from your usual dose. If you want a thorough look at this question, our dedicated page on whether you have to wean off Mounjaro walks through the pharmacology and the practical considerations in detail.

That said, some prescribers do choose to reduce dose before stopping, particularly if a patient is on a higher maintenance dose and wants a more gradual re-adjustment period, or where there are other clinical reasons to do so. This is an individualised decision, not a rule. If you are weighing up the options, our page on whether you should wean off Mounjaro explores the practical considerations in more depth, and our page on how to wean off Mounjaro covers what a step-down approach looks like if your prescriber recommends one.

For anyone considering stopping because of side effects rather than reaching a goal, it is worth knowing that GI effects (nausea, changes in appetite, digestive changes) often settle with time or at a lower dose. A conversation with your prescriber before stopping may reveal options you have not tried yet. You can read more about weight-loss treatment options more broadly if you are thinking about what the next chapter looks like.

The practical conversation to have with your prescriber

NICE's guidance on tirzepatide (TA1026) frames it as a treatment that should be reviewed at the six-month mark and periodically thereafter, assessing whether continued use remains appropriate. That review structure reflects the intended model: clinical oversight throughout, not just at the start. Stopping is part of that same oversight.

When you speak to your prescriber about discontinuing Mounjaro, useful things to cover include: your current dose, how long you have been on treatment, what weight-management plan you will follow after stopping, and whether there are any conditions that were being partly managed by the medicine (blood pressure and blood sugar can both be affected). Our clinical team takes this kind of review seriously at every stage of treatment. At nume, no repeat order is sent out without a fresh clinical review, and equally, stopping safely is something our prescribers are available to support. If you are thinking about whether treatment is right for you going forward, starting with a free consultation lets a prescriber assess your full picture. That is the right place to begin.